Global Methenamine Hippurate Tablets Market Is Predicted to Grow Around USD 14.74 Billion By 2030

The global Methenamine Hippurate Tablets Market Is Likely To Grow At A CAGR Value Of Around 6.51% By 2030

The global methenamine hippurate tablets market size was worth around USD 8.91 Billion in 2022 and is predicted to grow to around USD 14.74 Billion by 2030 with a compound annual growth rate (CAGR) of roughly 6.51% between 2023 and 2030.

The methenamine hippurate tablets industry refers to the production and sale of methenamine hippurate tablets which are medicines used for the treatment of urinary tract infections (UTIs) that are caused by bacteria. The infection affects any part of the urinary system in human anatomy including the urethra, kidneys, ureters, and bladder. These UTI-treating tablets are also known as methenamine salts. The fraternity is responsible for the research, production, distribution, and sale of methenamine hippurate tablets. Currently, pharmaceutical companies are one of the leading contributors toward the research and development of medicines During the forecast period, the industry is expected to witness steady growth since in the last 3 years, there have been several breakthrough research activities conducted surrounding further application and development of the medication.

The global methenamine hippurate tablets market is projected to grow owing to the increasing female population, which is most prone to contracting UTIs mainly due to the anatomy of the female urinary system. With the growing female population, the chances of more women contracting the disease also increase leading to higher demand in the industry. In addition to this, the infection can also be caused by certain medical conditions like diabetes, kidney stones, and urinary tract abnormality along with some types of birth control agents like diaphragms. These factors are additional contributors to the growth in the target consumer group for the fraternity.

Furthermore, the growing healthcare expenditure observed across the globe is crucial during the forecast period. The healthcare-related expenses are growing due to the increasing demand for healthcare services, the aging population, and the increasing prevalence of chronic diseases. The ongoing research activities directed toward technological advancements also work in the favor of the market size. New technologies and drug delivery systems are crucial aspects of technological growth.

While the growth rate may be steady for the methenamine hippurate tablets industry, it is also expected to encounter certain growth restrictions, especially in terms of rising concerns over the adverse effects of the medicines. Some of the side effects include gastrointestinal disturbances, skin rashes, and allergic reactions. Unless market players can provide medicines with zero unwanted medical impact, the industry may not reach its true potential. Additionally, factors such as limited awareness amongst patients especially in underdeveloped economies, availability of alternative medicines, and patent expiry are other roadblocks against the market growth.

The growing demand for preventive care may provide growth opportunities while the limited availability in developing nations could challenge market growth.

The global methenamine hippurate tablets market is segmented based on application, type, distribution channel, end-users, and region.

Based on application, the global market segments are healthcare-associated UTIs and uncomplicated UTIs. In 2022, the industry registered the highest growth in the uncomplicated UTIs segment. This is mainly because this type of infection is generally caused by bacteria which can be treated with methenamine hippurate tablets since the bacteria is susceptible to the medicines and can be treated with it alone. However, healthcare-associated UTIs are generally caused by more serious conditions and may be the result of antibiotic-resistant bacteria. In such cases, medical professionals may prescribe the tablet in combination with other antibiotics. In the United States, UTIs are estimated to be responsible for over 8.1 million medical visits every year.

Based on type, the methenamine hippurate tablets industry divisions are 6 tablets/ bottle and 20 tablets/bottle. In 2022, the industry witnessed the highest growth in the 20 tablets/bottle segment since this type of medication is more common in people who may be in need of long-term UTI prophylaxis. Since the number of tablets in this segment is more, the entire treatment plan may be more cost-effective as compared to bottles with a lesser number of tablets. The 6 tablets/bottle segment is more commonly used for patients who require shorter UTI prophylaxis or people who prefer smaller sizes for better portability. The average cost of these tablets with all dosages and packaging sizes combined is around $32 USD per 100 tablets.

Based on distribution channel, the industry divisions are online pharmacy, hospital pharmacy, and retail pharmacy.

North America is expected to lead the global methenamine hippurate tablets market owing to the high awareness rate amongst the population about the benefits of using the medication. Furthermore, the presence of key pharmaceutical industry players who are regularly investing in the development of new methenamine hippurate-based products is expected to work in the favor of the regional industry. In Europe, the growth may be driven by the rising demand for preventive care as well as the growing demand for over-the-counter medications. Africa may not register high CAGR mainly due to a lack of awareness and the absence of adequate medical architecture in the region along with a lack of financial assistance leading to many people not having proper access to medical treatments.

This review is based on a report by Zion Market Research, titled “Methenamine Hippurate Tablets Market By Application (Healthcare-associated UTIs and Uncomplicated UTIs), By Type (6 Tablets/ Bottle and 20 Tablets/Bottle), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, and Retail Pharmacy), By End-Users (Homecare, Hospitals, Specialty Clinics, Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030.”- Report at https://www.zionmarketresearch.com/report/methenamine-hippurate-tablets-market

Recent Developments:

• In March 2022, Hospital Pharmacy Europe posted a review on methenamine hippurate. In the post, they confirmed that the effectiveness of the methenamine hippurate medication is similar to low-dose prophylactic antibiotics for treating or preventing recurrent urinary tract infections
• In May 2019, The Medicine Products Agencies in Denmark, Sweden, and the United Kingdom approved the pharmaceutical Methenamine hippurate EQL Pharma, tablet 1g for commercial purposes

The global methenamine hippurate tablets market is home to players like:

• Almirall
• S.A.
• Mylan N.V.
• Merck & Co. Inc.
• Cadila Healthcare Ltd.
• Pfizer Inc.
• Dr. Reddy's Laboratories Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• West-Ward Pharmaceuticals Corp.
• Abbott Laboratories
• Glenmark Pharmaceuticals Ltd.
• Bausch Health Companies Inc.
• Procter & Gamble Co.
• Jubilant Life Sciences Ltd.
• Lupin Pharmaceuticals Inc.
• Cipla Ltd.
• Amneal Pharmaceuticals LLC.
• Allergan plc.
• Novartis AG.
• Sanofi S.A.

The global methenamine hippurate tablets market is segmented as follows:

By Application

• Healthcare-associated UTIs
• Uncomplicated UTIs

By Type

• 6 Tablets/ Bottle
• 20 Tablets/Bottle

By Distribution Channel

• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

By End-Users

• Homecare, Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com